Dogwood Q2 net loss $11.5M; Halneuron Phase 2b on track, 217 patients enrolled

Dogwood Therapeutics, Inc.

Net loss $11.5M ($0.34/share) vs $3.8M ($1.99/share) in Q2 2025; includes $6.7M non-cash IPR&D impairment.
Cash $9.6M provides runway through Q4 2026 Phase 2b readout; R&D $3.2M, G&A $1.6M.
Halneuron Phase 2b CINP trial: 217 patients enrolled, top-line results expected fall 2026; 12-week extension study started.
SP16 granted FDA IND approval; NCI-funded study at UVA to start H2 2026.
Appointed Iain Dukes (OrbiMed) as Scientific Advisory Board Chair; legacy antiviral partnership worth up to $100M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.